Nucleoside reverse transcriptase inhibitors (NRTIs) induce proinflammatory cytokines in the CNS via Wnt5a signaling

Ting Wu¹, Juan Zhang¹, Mingxing Geng¹, Shao-Jun Tang², Wenping Zhang¹ & Jianhong Shu¹

HAART is very effective in suppressing HIV-1 replication in patients. However, patients staying on long-term HAART still develop various HIV-associated neurological disorders, even when the viral load is low. The underlying pathogenic mechanisms are largely unknown. Emerging evidence implicated that persistent neuroinflammation plays an important role in NeuroAIDS. Although residual virus or viral proteins are commonly thought as the causal factors, we are interested in the alternative possibility that HAART critically contributes to the neuroinflammation in the central nervous system (CNS). To test this hypothesis, we have determined the effect of NRTIs on the expression of proinflammatory cytokines in the various CNS regions. Mice (C57Bl/6) were administered with AZT (Zidovudine 100 mg/kg/day), 3TC (Lamivudine 50 mg/kg/day) or D4T (Stavudine 10 mg/kg/day) for 5 days, and cortices, hippocampi and spinal cords were collected for immunoblotting. Our results showed that NRTI administration up-regulated cytokines, including IL-1β, TNF-α and IL-6 in various CNS regions. In addition, we found that NRTIs also up-regulated Wnt5a protein. Importantly, BOX5 attenuated NRTI-induced cytokine up-regulation. These results together suggest that NRTIs up-regulate proinflammatory cytokines via a Wnt5a signaling-dependent mechanism. Our findings may help understand the potential pathogenic mechanisms of HAART-associated NeuroAIDS and design effective adjuvants.

Received: 18 January 2017  
Accepted: 27 April 2017  
Published: xx xx xxxx

OPEN
Chronic neuroinflammation is implicated in various neurological diseases, including HAND. A consistent finding in the postmortem biopsies of HIV patients is neuroinflammation, as indicated by the presence of activated microglia and up-regulated pro-inflammatory cytokines. HIV infection and toxic viral proteins such as gp120 and Tat are commonly thought as the cause of neuroinflammation in HIV patients. Indeed, the activity of gp120 and Tat in inducing neuroinflammation has been demonstrated in cultured glial cells and animal models. However, the potential contribution of HAART drugs to the manifestation of persistent neuroinflammation has not been conclusively tested. Because HIV patients usually stay on long-term HAART, this question is clinically relevant.

In this study, we test the hypothesis that long-term administration of NRTIs to mice induces neuroinflammation. We measured the expression level of IL-1β, TNF-α and IL-6 in different CNS regions from mice that were administered with AZT (Zidovudine 100 mg/kg/day), 3TC (Lamivudine 50 mg/kg/day) or D4T (Stavudine 10 mg/kg/day) for 5 days by western blotting. Our results showed that NRTIs up-regulated the cytokines in CNS, and that Wnt5a signaling played a critical role in NRTIs-induced cytokine up-regulation.

**Result**

**NRTIs up-regulate the expression of inflammatory cytokines in the CNS.** Persistent neuroinflammation is considered to contribute to the development of HAND. As HAART is the currently common treatment to suppress HIV replication in patients, we wanted to determine the potential effect of NRTIs, the essential components in HAART, on neuroinflammation in the CNS. Mice (C57Bl/6, males, 6–8 weeks) were subcutaneously injected with AZT (100 mg/kg/day), 3TC (50 mg/kg/day) or D4T (10 mg/kg/day) for 2, 5, 10, or 14 days and CNS tissues including cortices, hippocampi and spinal cords, were collected at the end of NRTIs treatment. Western blotting analysis was performed to determine the expression levels of IL-1β, TNF-α and IL-6.

Preliminary experiments indicated an increase of the cytokines was already evident at day 5 after NRTIs administration. Thus, we focused our analysis on this time point to save animals.

As shown in Fig. 1, IL-6, TNF-α and IL-1β in cerebral cortices, hippocampi and spinal cords were significantly increased after NRTIs treatment (Fig. 1). Among the NRTIs, 3TC (50 mg/kg/day) showed the most evident effect on cerebral cytokines (IL-1β: 2.18 folds, p < 0.01; TNF-α: 3.22 folds, p < 0.01; IL-6: 2.56 folds, p < 0.01) (Fig. 1a). AZT (100 mg/kg/day), 3TC (50 mg/kg/day) and D4T (10 mg/kg/day) also caused different magnitudes of cytokine up-regulation in hippocampi and spinal cords (Fig. 1b,c). These results suggest that NRTIs induce pro-inflammatory cytokines up-regulation in different regions of the CNS.
NRTIs up-regulate Wnt5a in the CNS. Wnt5a is emerging as a major inflammatory regulator\(^{35–37}\) and is up-regulated in the spinal cord of ‘pain-positive’ HIV patients on HAART\(^{38}\). We determined if AZT, 3TC and D4T administration (5 days) up-regulated Wnt5a protein in the cerebral cortex (Fig. 2a), the hippocampus (Fig. 2b) and the spinal cord (Fig. 2c). In the cerebral cortex, Wnt5a was significantly increased in the 3TC group (2.13 fold; \(p < 0.01\)). All three NRTIs induced significant Wnt5a increase in the hippocampus (AZT: 2.06 folds, \(p < 0.01\); 3TC: 2.61 folds, \(p < 0.01\); D4T: 1.88 folds, \(p < 0.001\)) and the spinal cord (AZT: 3.55 folds, \(p < 0.01\); 3TC: 4.40 folds, \(p < 0.001\); D4T: 3.42 folds, \(p < 0.01\)). We also performed immunohistochemistry staining of Wnt5a in the spinal cord and observed that evident increase of Wnt5a after AZT, 3TC or D4T administration (5 days) (Fig. 2d). These data confirm that Wnt5a is up-regulated in the CNS by NRTIs.

Wnt5a antagonists attenuate NRTIs-induced cytokine up-regulation in the CNS. Wnt5a was reported to regulate HIV-1 gp120-induced cytokine expression in the spinal cord\(^{39}\). To investigate the potential role of Wnt5a in NRTI-induced cytokines in the CNS, we determined the effect of Wnt5a antagonist BOX5. BOX5 (10 \(\mu\)g/day)\(^{40}\) was administered via the mouse nasal cavity at 3 hours after each NRTI injection. The cerebral cortex, hippocampus and spinal cord were collected for Western blotting after 5 days of drugs administration. We observed that BOX5 administration significantly attenuated NRTIs-induced up-regulation of inflammatory cytokines in the CNS regions (Fig. 3). These results suggest that Wnt5a at least partly mediated the cytokine up-regulation induced by NRTIs. Interestingly, BOX5 treatment also significantly reduced the expression of Wnt5a in the CNS (Fig. 4). This observation indicates that Wnt5a signaling plays a key role in the Wnt5a up-regulation induced by NRTIs.

Discussion

In this study, we have tested the hypothesis that NRTIs cause neuroinflammation in the CNS. It is well documented that NRTIs can cause neurotoxicity\(^{41–43}\), especially in the peripheral nervous system\(^{44–46}\), but comprehensive investigation on the effect of NRTIs on CNS neuroinflammatory has not been reported. We systematically measure the expression of three cytokines, including IL-1\(\beta\), TNF-\(\alpha\) and IL-6, after the administration of three NRTIs (AZT, 3TC, D4T) in three CNS regions (cortex, hippocampus and spinal cord). Our results show that all three tested NRTIs induce cytokine up-regulation in general, despite that drug-specific effects are observed for different NRTIs. Although it is commonly thought that residual virus and/or viral protein are the causal factors for the commonly observed persistent neuroinflammation in the CNS, our findings indicate that we need to at least include the antiretroviral regimens containing NRTIs as potential critical etiological factor underlying the neuroinflammation in the CNS of HIV patients on HAART. Although some ‘old’ NRTIs (e.g. AZT and d4T) that are no longer recommended for the first-line treatment are included in the study, this insight may have a general clinically-relevant implication, and is consistent with the reported up-regulation of inflammatory cytokines by other HAART components such as NNRTI and PI in the CNS\(^{45–47}\).

Cytokines such as IL-1\(\beta\), TNF-\(\alpha\) and IL-6 are implicated in inflammatory responses associated with various CNS damages\(^{48–51}\). Thus, NRTI-induced proinflammatory cytokines revealed in this study may directly contribute...
to the development of neuroAIDS/HAND\textsuperscript{52–56}. In support of this notion, Zheng et al. found that TNF-\(\alpha\) is involved in neuropathic pain induced by 2',3'-dideoxycytidine (ddC) in rats\textsuperscript{57}. This new understanding may add significant insights into the pathogenesis of neuroAIDS from the perspective of antiretroviral therapy. Flower et al. reported an anti-inflammatory activity of NRTIs (e.g. AZT and d4T) in primary human retinal pigment epithelium cells or Raji/TK+ cells\textsuperscript{58}. It will be interesting to examine if NRTIs have pro- and anti-inflammatory effects in different biological systems.

Our results further suggest a Wnt5a-mediated mechanism by which NRTIs up-regulate cytokines in the CNS. Specifically, we show that Wnt5a is also up-regulated by NRTIs (Fig. 2a,b,c), and that a specific antagonist of Wnt5a, BOX5, attenuates the NRTIs -induced cytokine up-regulation (Fig. 3). Although Wnt5a has been

**Figure 3.** Wnt5a antagonists attenuate NRTIs-induced cytokine up-regulation in the CNS. Protein levels of cytokine in cortex (a), hippocampus (b) and spinal cord (c) treated with NRTIs and BOX5 for 5 days. Data presented in graphs are means ± SEM from 5 mice per group *\(p < 0.05\), **\(p < 0.01\), ***\(p < 0.001\) vs vehicle.
suggested to regulate inflammation, including neuroinflammation, this study reports for the first time an important role of Wnt5a signaling in the regulation of NRTI-evoked CNS neuroinflammation.

Taken together, our findings suggest that HAART may contribute to neuroAIDS pathogenesis by inducing neuroinflammation in the CNS. Wnt5a signaling probably plays a critical role in this pathogenic process by regulating NRTIs-induced cytokines, which could directly contribute to neuroAIDS-related neurodegeneration (Fig. 5). This mechanistic understanding suggests controlling NRTI-induced neuroinflammation as a potential strategy to reduce the risk of neuroAIDS.

Figure 4. BOX5 inhibited the expression of wnt5a in the CNS. Protein levels of Wnt5a in cortex (a), hippocampus (b) and spinal cord (c) treated with NRTIs and BOX5 for 5 days. Data presented in graphs are means ± SEM from 5 mice per group *p < 0.05, **p < 0.01, ***p < 0.001 vs vehicle.
Materials and Methods

Animals and tissue dissection. All animals (C57BL/6 mice, male, 6–8 weeks) were purchased from Shanghai Ling Chang Biological Technology Co., Ltd. All procedures used in the study were approved by the Zhejiang Sci-tech University Experimental Animal Ethics Committee, and all experimental procedures were carried out in accordance with relevant guidelines and regulations. Specific experimental procedures are described below.

Cerebral cortex and hippocampus. Mice were euthanized with inhaled anesthesia ether, and heads were quickly removed and put into phosphate buffer saline (PBS) precooled on ice. The skulls of completely soaked heads were opened and the brains were removed to clean dishes. Cerebral cortices and hippocampi were carefully dissected and frozen immediately in liquid nitrogen. Frozen tissues were stored in a −80°C refrigerator. Spinal cord: The whole spines of euthanized mice were exposed by cutting along the spine skin on the back. After exposure, the spine was cut near the tail cavity. The spinal cord was flushed out with precooled PBS. Collected spinal cords were frozen in liquid nitrogen and stored at −80°C freezer.

NRTI Drugs. NRTI drugs: zidovudine (AZT), lamivudine (3TC) and stavudine (D4T) were purchased from Sigma (Sigma-Aldrich). NRTIs were dissolved in PBS to a final concentration of AZT (8 mg/ml), 3TC (4 mg/ml) and D4T (0.8 mg/ml) and stored at −20°C.

Subcutaneous (SC) injection. NRTIs were administered by SC injection. First, the injection site was disinfected with 75% alcohol. Skins of the back of the mouse was gently raised for slowly injecting the drug (0.25 ml/20 g) into the subcutaneous space. After injection, the injection site was pressed gently with alcohol wipes for a moment to prevent drug leakage. Injection volume: 0.25 ml/20 g/day.

Nasal drug administration. Mice were administered with BOX5 (dissolved in PBS to the concentration of 0.5 μg/μL) by nasal dripping as previously described, at 3 hours after NRTI injection. Briefly, a mouse was placed into a fixator tube (a centrifuge tube about the size of the mouse so that the animal can easily claw in). A small hole was made in the bottom of the fixator to expose the nostrils. One person held the animal with the left hand, and gently fixed the mouse head with the right hand to properly expose the nostrils. Another person applied the drug to the nostrils with a 10 μL pipette. Left and right nostrils of mouse were separately administered with BOX5 (10 μL). Drug solution drops were applied to the nostril slowly, usually with one drop every few seconds, and the next drop was applied only after the previous one was completely absorbed. After completing drug application to one nostril, the same procedure was performed to the other nostril. The time interval was about 1 minute. The animal was released from the fixation device after the completion of the whole procedure. Injection volume: 10 μL each nostril per day.

Western blotting and antibodies. Collected tissues were homogenized in cell lysis buffer (Beyotime Institute of Biotechnology), with protease inhibitors (Biotool). The homogenates were centrifugated for 10 min (12,000 g), and protein concentration in the supernatant was measured using the BCA Protein Assay Kit (BIOMIGA). Equal amounts of total protein (40–60 μg) were loaded and separated on 12% SDS-PAGE by electrophoresis (120 V, 90–120 min). Proteins on SDS-PAGE were blotted onto PVDF membranes (100 V, 90–120 min). The membranes were blocked with 5% skim milk dissolved in TBST (20mMTris-HCl,150mMNaCl,0.05%Tween-20) solution for 2 h, and incubated sequentially with primary antibodies in TBST against IL-6 (1:10000, abcamab7737), IL-1β (1:2000, R&D Systems, AF-401-NA), TNF-α (1:1000, abcamab1793), Wnt5a (1:2500, abcamab72583), α-tubulin (1:10000, Proteintech,66031-1-lg) or GAPDH (1:10000, Santa Cruz sc-25778) for 2 h. After washes with TBST3 times for 10 minutes each and the membranes were incubated with goat anti-rabbit IgG (1:30000, abcamab97051) or goat anti-mouse IgG (1:30000 abcamab97023) secondary antibody
conjugated with horseradish peroxidase (HRP) in TBST, After washes with TBST3 times for 10 minutes each and the protein bands were visualized by ECL (Advansta). Tubulin and GAPDH were used as loading controls.

**Immunohistochemistry.** Immunohistochemistry was performed as described65. Briefly, paraffin sections were collected and deparaffinized. Endogenous peroxidase was blocked with 0.3% hydrogen peroxide in methanol. The sections were incubated in EDTA (pH 8.0) buffer at 95–100°C for 20 min for antigen repair. The pre-treated sections were incubated with primary antibody at room temperature (25°C) for 0.5–1 h, followed by incubation with secondary antibody for 30 min and staining with DAB (Gene Technology). The slides were lightly counterstained with hematoxylin, rinsed with distilled water, dehydrated in ethanol and mounted.

**References**

1. Barré-Sinoussi, F. et al. Isolation of a T-lymphotrophic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). *Science* **220**, 868–871 (1983).

2. HIV/AIDS global situation and trends. http://www.who.int/gho/hiv/en (2015).

3. Ghosh, A. K., Osswald, H. L. & Prato, G. Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS. *J. Med. Chem.* **59**, 5172–5208, doi:10.1021/acs.jmedchem.5b01697 (2016).

4. James, C. W., McNelis, K. C., Malatia, M. D., Cohen, D. M. & Szabo, S. Central nervous system toxicity and amnepivir oral solution. *Ann Pharmacotherapy.* **36**, 174 (2002).

5. Vivithanaporn, P., Ashchop, E. L., Acharjee, S., Baker, G. B. & Power, C. HIV protease inhibitors disrupt astrocytic glutamate transporter function and neurobehavioral performance. *AIDS* **30**, 543–552, doi:10.1097/QAD.0000000000000955 (2016).

6. Heaton, R. K. et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy CHARTER Study. *Neurology.* **75**, 2087–2096, doi:10.1212/WNL.0b013e318202d727 (2010).

7. Simioni, S. et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. *Aids.* **24**, 1243–1250, doi:10.1097/QAD.0b013e328354a7b8 (2010).

8. Gongvatana, A. et al. Progressive cerebral injury in the setting of chronic HIV infection and antiretroviral therapy. *Journal of NeuroVirology.* **19**, 209–218 (2013).

9. Akay, C. et al. Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system. *Journal of Neurovirology.* **20**, 39–53, doi:10.1007/s13365-013-0227-1 (2014).

10. van Oosterhout, J. J. et al. Stavudine toxicity in adult longer-term ART patients in Blantyre, Malawi. *PloS One* **7**, e42029, doi:10.1371/journal.pone.0042029 (2012).

11. Abers, M. S., Shandera, W. X. & Kass, J. S. Neurological and psychiatric adverse effects of antiretroviral drugs. *CNS Drugs.* **28**, 131–145, doi:10.1007/s40263-013-0132-4 (2014).

12. Xu, H. et al. Lamivudine/telbivudine-associated neumopathy: neurogenic damage, mitochondrial dysfunction and mitochondrial DNA depletion. *J Clin Pathol.* **67**, 999–1005, doi:10.1136/jclinpath-2013-202069 (2014).

13. Pettersen, J. A. et al. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. *Ann. Neurol.* **59**, 816–824, doi:10.1002/ana.20816 (2006).

14. Schindzielorz, A., Pike, I., Daniels, M., Pacelli, L. & Smaldone, L. Rates and risk factors for adverse events associated with didanosine in the expanded access program. *Clin Infect Dis.* **19**, 1076–1083 (1994).

15. Cepeda, J. A. & Wilks, D. Excess peripheral neuropathy in patients treated with hydroxyurea plus didanosine and stavudine for HIV infection. *AIDS.* **14**, 332–333 (2000).

16. Kelleher, T., Cross, A. & Dunkle, L. Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine. *Clinical Therapeutics.* **21**, 1182–1192 (1999).

17. Blanche, S. et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. *Lancet.* **354**, 1084–1089 (1999).

18. Moodley, A., Bhola, S., Omar, F. & Mogambery, J. Antiretroviral therapy-induced Leber’s hereditary optic neuropathy. *Southern African Journal of HIV Medicine* **15**, 69–71, doi:10.7196/Sajhim.1056 (2014).

19. Koctur, C. A. et al. AZT-induced mitochondrial toxicity: an epigenetic paradigm for dysregulation of gene expression through mitochondrial oxidative stress. *Physiological Genomics.* **47**, 447–454, doi:10.1152/physgen.00045.2015 (2015).

20. Kohler, J. J., Hosseini, S. H. & Lewis, W. Mitochondrial DNA impairment in nucleoside reverse transcriptase inhibitor-associated cardiomyopathy. *Chemical Research in Toxicology.* **21**, 990–996, doi:10.1021/tx0800219 (2008).

21. Shah, A. et al. Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapists. *Neurotox Res* **30**, 677–697, doi:10.1007/s12640-016-9646-0 (2016).

22. Zheng, W. et al. IL-10 mediated by herpes simplex virus vector reduces neuropathic pain induced by HIV gp120 combined with ddlC in rats. *Mol Pain.* **10**, 49, doi:10.1186/1744-8609-10-49 (2014).

23. Yuan, S. B. et al. A Wnt5a signaling pathway in the pathogenesis of HIV-1 gp120-induced pain. *Pain.* **156**, 1311–1319, doi:10.1097/j.pain.0000000000000177 (2015).

24. Shi, Y., Gelm, B. B., Lissincchia, J. G. & Tang, S. J. Chronic-pain-associated astrocytic reaction in the spinal cord dorsal horn of human immunodeficiency virus-infected patients. *J. Neurosci.* **32**, 10833–10840, doi:10.1523/JNEUROSCI.5628-11.2012 (2012).

25. Shah, A. & Kumar, A. HIV-1 gp120-mediated increases in IL-8 production in astrocytes are mediated through the NF-kappa B. *Brain* **22**, 39–13, doi:10.1038/s41598-017-03446-w
64. Wang, X.
63. Li, B.
62. Halleskog, C. & Schulte, G. WNT-3A and WNT-5A counteract lipopolysaccharide-induced pro-inflammatory changes in mouse  
61. Zhao, Y.
60. Nakamura, K.
59. George, S. J. Wnt pathway - A new role in regulation of inflammation.  
57. Zheng, X. X.
53. Soontornniyomkij, V.
55. Bade, A. N.
51. Peferoen, L. A. N.
49. Montesinos, J., Alfonso-Loeches, S. & Guerri, C. Impact of the Innate Immune Response in the Actions of Ethanol on the Central  
48. Vezzani, A. & Viviani, B. Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability.  
45. O’Mahony, S. M., Myint, A. M., Steinbusch, H. & Leonard, B. E. Efavirenz induces depressive-like behaviour, increased stress  
43. Arenas-Pinto, A.
42. Warren, G. et al. Amphiphilic Cationic Nanogels as Brain-Targeted Carriers for Activated Nucleoside Reverse Transcriptase  
41. Abers, M. S., Shandera, W. X. & Kass, J. S. Neurological and Psychiatric Adverse Effects of Antiretroviral Drugs.  
38. Shi, Y., Shu, J., Gelman, B. B., Lisinicchia, J. G. & Tang, S. J. Wnt signaling in the pathogenesis of human-HIV-associated pain  
36. Bhatt, P. M. & Malgor, R. Wnt5a: A player in the pathogenesis of atherosclerosis and other inflammatory disorders.  
35. Pereira, C., Schaer, D. J., Bachli, E. B., Kurrer, M. O. & Schoedon, G. Wnt5a/CaMKII signaling contributes to the inflammatory  
34. Bhalja, S. et al. Neuroimmunomodulatory properties of Wnt-5A in the pathogenesis of Alzheimer’s disease: A review.  
33. Montesinos, J., Alfonso-Loeches, S. & Guerri, C. Impact of the Innate Immune Response in the Actions of Ethanol on the Central  
32. Shi, Y., Shu, J., Gelman, B. B., Lisinicchia, J. G. & Tang, S. J. Wnt signaling in the pathogenesis of human-HIV-associated pain  
31. Zheng, X. X.
30. George, S. J. Wnt pathway - A new role in regulation of inflammation.  
29. O’Mahony, S. M., Myint, A. M., Steinbusch, H. & Leonard, B. E. Efavirenz induces depressive-like behaviour, increased stress  
28. Shi, Y., Shu, J., Gelman, B. B., Lisinicchia, J. G. & Tang, S. J. Wnt signaling in the pathogenesis of human-HIV-associated pain  
27. Zheng, X. X.
26. Shi, Y., Shu, J., Gelman, B. B., Lisinicchia, J. G. & Tang, S. J. Wnt signaling in the pathogenesis of human-HIV-associated pain  
25. O’Mahony, S. M., Myint, A. M., Steinbusch, H. & Leonard, B. E. Efavirenz induces depressive-like behaviour, increased stress  
24. Bhalja, S. et al. Neuroimmunomodulatory properties of Wnt-5A in the pathogenesis of Alzheimer’s disease: A review.  
23. Montesinos, J., Alfonso-Loeches, S. & Guerri, C. Impact of the Innate Immune Response in the Actions of Ethanol on the Central  
22. Shi, Y., Shu, J., Gelman, B. B., Lisinicchia, J. G. & Tang, S. J. Wnt signaling in the pathogenesis of human-HIV-associated pain  
21. Zheng, X. X.
20. Shi, Y., Shu, J., Gelman, B. B., Lisinicchia, J. G. & Tang, S. J. Wnt signaling in the pathogenesis of human-HIV-associated pain  
19. O’Mahony, S. M., Myint, A. M., Steinbusch, H. & Leonard, B. E. Efavirenz induces depressive-like behaviour, increased stress  
18. Bhalja, S. et al. Neuroimmunomodulatory properties of Wnt-5A in the pathogenesis of Alzheimer’s disease: A review.  
17. Montesinos, J., Alfonso-Loeches, S. & Guerri, C. Impact of the Innate Immune Response in the Actions of Ethanol on the Central  
16. Shi, Y., Shu, J., Gelman, B. B., Lisinicchia, J. G. & Tang, S. J. Wnt signaling in the pathogenesis of human-HIV-associated pain  
15. O’Mahony, S. M., Myint, A. M., Steinbusch, H. & Leonard, B. E. Efavirenz induces depressive-like behaviour, increased stress  
14. Bhalja, S. et al. Neuroimmunomodulatory properties of Wnt-5A in the pathogenesis of Alzheimer’s disease: A review.  
13. Montesinos, J., Alfonso-Loeches, S. & Guerri, C. Impact of the Innate Immune Response in the Actions of Ethanol on the Central  
12. Shi, Y., Shu, J., Gelman, B. B., Lisinicchia, J. G. & Tang, S. J. Wnt signaling in the pathogenesis of human-HIV-associated pain  
11. O’Mahony, S. M., Myint, A. M., Steinbusch, H. & Leonard, B. E. Efavirenz induces depressive-like behaviour, increased stress  
10. Bhalja, S. et al. Neuroimmunomodulatory properties of Wnt-5A in the pathogenesis of Alzheimer’s disease: A review.  
9. Montesinos, J., Alfonso-Loeches, S. & Guerri, C. Impact of the Innate Immune Response in the Actions of Ethanol on the Central  
8. Shi, Y., Shu, J., Gelman, B. B., Lisinicchia, J. G. & Tang, S. J. Wnt signaling in the pathogenesis of human-HIV-associated pain  
7. O’Mahony, S. M., Myint, A. M., Steinbusch, H. & Leonard, B. E. Efavirenz induces depressive-like behaviour, increased stress  
6. Bhalja, S. et al. Neuroimmunomodulatory properties of Wnt-5A in the pathogenesis of Alzheimer’s disease: A review.  
5. Montesinos, J., Alfonso-Loeches, S. & Guerri, C. Impact of the Innate Immune Response in the Actions of Ethanol on the Central  
4. Bhalja, S. et al. Neuroimmunomodulatory properties of Wnt-5A in the pathogenesis of Alzheimer’s disease: A review.  
3. Montesinos, J., Alfonso-Loeches, S. & Guerri, C. Impact of the Innate Immune Response in the Actions of Ethanol on the Central  
2. Shi, Y., Shu, J., Gelman, B. B., Lisinicchia, J. G. & Tang, S. J. Wnt signaling in the pathogenesis of human-HIV-associated pain  
1. O’Mahony, S. M., Myint, A. M., Steinbusch, H. & Leonard, B. E. Efavirenz induces depressive-like behaviour, increased stress
Additional Information

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017